1. DDX3X and specific initiation factors modulate FMR1 repeat-associated non-AUG-initiated translation.
- Author
-
Linsalata AE, He F, Malik AM, Glineburg MR, Green KM, Natla S, Flores BN, Krans A, Archbold HC, Fedak SJ, Barmada SJ, and Todd PK
- Subjects
- Animals, Ataxia genetics, Cells, Cultured, DEAD-box RNA Helicases genetics, Drosophila Proteins genetics, Drosophila melanogaster, Eukaryotic Initiation Factors genetics, Female, Fragile X Mental Retardation Protein genetics, Fragile X Syndrome genetics, HEK293 Cells, HeLa Cells, Humans, Immunoprecipitation, Male, Phenotype, Reverse Transcriptase Polymerase Chain Reaction, Tremor genetics, Ataxia metabolism, DEAD-box RNA Helicases metabolism, Drosophila Proteins metabolism, Eukaryotic Initiation Factors metabolism, Fragile X Mental Retardation Protein metabolism, Fragile X Syndrome metabolism, Tremor metabolism
- Abstract
A CGG trinucleotide repeat expansion in the 5' UTR of FMR1 causes the neurodegenerative disorder Fragile X-associated tremor/ataxia syndrome (FXTAS). This repeat supports a non-canonical mode of protein synthesis known as repeat-associated, non-AUG (RAN) translation. The mechanism underlying RAN translation at CGG repeats remains unclear. To identify modifiers of RAN translation and potential therapeutic targets, we performed a candidate-based screen of eukaryotic initiation factors and RNA helicases in cell-based assays and a Drosophila melanogaster model of FXTAS. We identified multiple modifiers of toxicity and RAN translation from an expanded CGG repeat in the context of the FMR1 5'UTR. These include the DEAD-box RNA helicase belle/DDX3X, the helicase accessory factors EIF4B/4H, and the start codon selectivity factors EIF1 and EIF5. Disrupting belle/DDX3X selectively inhibited FMR1 RAN translation in Drosophila in vivo and cultured human cells, and mitigated repeat-induced toxicity in Drosophila and primary rodent neurons. These findings implicate RNA secondary structure and start codon fidelity as critical elements mediating FMR1 RAN translation and identify potential targets for treating repeat-associated neurodegeneration., (© 2019 The Authors.)
- Published
- 2019
- Full Text
- View/download PDF